Visterra is a biologics research and early-stage clinical development company focused on creating therapies for patients suffering from immune-mediated and other challenging diseases. The company operates in the biotechnology sector, primarily serving patients with conditions in nephrology, rheumatology, transplant immunology, and neurology. Visterra's business model revolves around the research, development, and early clinical testing of biologic drugs, leveraging cutting-edge technologies to engineer novel therapies. The company generates revenue through partnerships, licensing agreements, and the eventual commercialization of its developed therapies. As part of the Otsuka family of companies, Visterra benefits from the support and stability of a long-established global entity while maintaining the agility and innovation of a smaller organization. The company also offers a Co-Op program to provide students with valuable industry experience and exposure to innovative research and technologies.

Keywords: biologics, immune-mediated diseases, nephrology, rheumatology, transplant immunology, neurology, early-stage clinical development, biotechnology, innovative therapies, Otsuka family.